Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 13Plasma cell 9Thoracic 2Other hematologic neoplasm 2CNS 2Breast 2Other solid neoplasm 1Myeloid 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1

Interventions

Fulvestrant 81Letrozole 74Paclitaxel 71pembrolizumab 67Specimen Handling 63Trastuzumab 60Carboplatin 55Magnetic Resonance Spectroscopy 50ribociclib 47Capecitabine 47Anastrozole 45palbociclib 44pertuzumab 43Tamoxifen 38Cyclophosphamide 38exemestane 37abemaciclib 37Biopsy 35trastuzumab deruxtecan 30Docetaxel 28Taxes 27Gemcitabine 25Radiotherapy 24Surveys and Questionnaires 23130-nm albumin-bound paclitaxel 23Standard of Care 21Blood Specimen Collection 21sacituzumab govitecan 20olaparib 20eribulin 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
tocilizumab × Breast × 90 days × Clear all
NCT05846789 2026-05-08

SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers

Indiana University

Phase 2 Recruiting
168 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03424005 2026-03-16

Morpheus-panBC

Hoffmann-La Roche

Phase 1/2 Recruiting
792 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡